Showing results (181-190 of 617) with videos related to

Sort By:
Pageof 62
Frontiers in Immunology|May 2, 2022
Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic SyndromeAndreas Reiter, Guillaume Lefevre, Maria C Cid, et al.
Allergy|October 7, 2022
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromesPeter Valent, Amy D Klion, Florence Roufosse, et al.
British Journal of Haematology|April 5, 2016
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myelomaTamara J Dunn, Shira Dinner, Elizabeth Price, et al.
Leukemia Research|June 11, 2013
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomesAlexander E Sherman, Gabriela Motyckova, K Rebecca Fega, et al.
Leukemia Research|February 14, 2014
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaDaniel J Deangelo, Donna Neuberg, Philip C Amrein, et al.
Haematologica|August 10, 2023
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemiaAndrew Hantel, Marlise R Luskin, Irum Khan, et al.
Blood|January 10, 2009
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification systemOlga K Weinberg, Mahesh Seetharam, Li Ren, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2010
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignanciesEdwin P Alyea, Daniel J DeAngelo, Jeffrey Moldrem, et al.
British Journal of Haematology|February 22, 2017
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosisSrdan Verstovsek, Michael R Savona, Ruben A Mesa, et al.
International Journal of Hematology|May 27, 2018
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myelomaShira Dinner, Tamara J Dunn, Elizabeth Price, et al.
Pageof 62